SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : IGT Pharma (V.IGT) Anti-Cancer Blockbuster!!
IGT 16.60-1.1%Oct 30 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bruce Lock who wrote (62)2/24/1999 7:01:00 PM
From: Spiney  Read Replies (1) of 86
 

IGT starts human trial with Anhydrovinblastine

IGT Pharma Inc IGT
Shares issued 8,819,820 Feb 23 close $0.83
Wed 24 Feb 99 News Release
Mr. Bruce Schmidt reports
The first patient has been treated with IGT's new drug, Anhydrovinblastine.
The clinical trial is a phase 1 study for the use of Anhydrovinblastine in
the treatment of advanced solid tumours including non-small cell lung
cancer. This is a single centre, open label, non-randomized phase 1 study.
This study will be conducted at the Roswell Park Cancer Institute in
Buffalo, N.Y. and will assess the safety and tolerability of
Anhydrovinblastine in these patients.
The study will enroll up to 30 patients with advanced solid cancers. The
clinical trial will determine the maximum tolerated dose and the dose
limiting toxicities of AVLB on an escalating dose basis. The clinical
investigators will assess the safety profile of AVLB, establish the
recommended dose schedule for future phase 2 trials, determine drug
kinetics and look for evidence of antitumour activity.
Roswell Park Cancer Institute is a division of the New York State
Department of Health and a national cancer institute designated
comprehensive cancer centre. Roswell Park is the nation's first cancer
research, treatment and education centre and the third largest.
Gary N. Schwartz has been appointed to the oncology advisory committee.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News